Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-082020 · 48 citations
2. 2Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer2015 · 1,432 citations
3. 3Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).2018 · 24 citations
4. 4Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer2013 · 2,248 citations
5. 5Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer2004 · 5,049 citations